A total of @ patients were randomly assigned to receive guselkumab ( @ mg at weeks @ and @ and every @ weeks thereafter , @ mg every @ weeks , @ mg at weeks @ and @ and every @ weeks thereafter , @ mg every @ weeks , or @ mg at weeks @ and @ and every @ weeks thereafter ) through week @ , placebo , or adalimumab ( standard dosage for psoriasis ) .